NK Cells

William Richard Childs, Jeremy Mark Pantin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Natural killer (NK) cells are innate immune lymphocytes that express CD56 and lack CD3 surface antigens. NK cells do not require the presence of specific tumor antigen for the recognition and killing of cancer cells. NK cell recognition of tumor targets is regulated through a balance of activating and inhibitory signals. NK cells also have the ability to directly kill target cells through antibodydependent cell cytotoxicity (ADCC) via the membrane Fc-? receptor III (CD16) which binds to IgG antibodies and can also indirectly induce tumor apoptosis through cytokine secretion, directly through the perforin-granzyme pathway, or through death-receptor ligands such as TRAIL or Fas ligand expressed on their cell surfaces. Tumors with low HLA class I expression are more susceptible to NK cell cytotoxicity. Adoptive infusion of allogeneic NK cells in patients who lack MHC class I molecules for one or more KIRs present in the donor may overcome NK cell-mediated KIR inactivation. Agents that increase surface expression of cellular death-receptors which render tumors more susceptible to NK cell cytotoxicity include bortezomib and depsipeptide. In vitro expanded autologous NK cells isolated from patients with cancers have been shown to exhibit significantly more cytotoxicity when tumors were pretreated with bortezomib compared with untreated tumor controls. Combining adoptive NK cell transfer with monoclonal antibody therapy could augment NK cell-mediated ADCC.

Original languageEnglish (US)
Title of host publicationCancer Therapeutic Targets
PublisherSpringer New York
Pages399-408
Number of pages10
Volume1-2
ISBN (Electronic)9781441907172
ISBN (Print)9781441907165
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Natural Killer Cells
Cytotoxicity
Tumors
Death Domain Receptors
Neoplasms
Depsipeptides
Granzymes
Perforin
Fas Ligand Protein
Lymphocytes
Neoplasm Antigens
Surface Antigens
Immunoglobulin G
CD3 Antigens
Monoclonal Antibodies
Cells
Apoptosis
Cytokines
Ligands
Membranes

Keywords

  • ADCC
  • Antibody-dependent cell cytotoxicity (ADCC)
  • CAR
  • Chimeric antigen receptors (CAR)
  • Clinical trials
  • Effector assessment
  • IL-2 activation
  • In cancer
  • In vitro and in vivo susceptibility
  • Interleukin-2 (IL-2)
  • Killer immunoglobulin-like receptors (KIRs)
  • KIR-mediated inactivation of
  • Natural killer (NK) cells
  • Tumor susceptibility

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Childs, W. R., & Pantin, J. M. (2017). NK Cells. In Cancer Therapeutic Targets (Vol. 1-2, pp. 399-408). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_32

NK Cells. / Childs, William Richard; Pantin, Jeremy Mark.

Cancer Therapeutic Targets. Vol. 1-2 Springer New York, 2017. p. 399-408.

Research output: Chapter in Book/Report/Conference proceedingChapter

Childs, WR & Pantin, JM 2017, NK Cells. in Cancer Therapeutic Targets. vol. 1-2, Springer New York, pp. 399-408. https://doi.org/10.1007/978-1-4419-0717-2_32
Childs WR, Pantin JM. NK Cells. In Cancer Therapeutic Targets. Vol. 1-2. Springer New York. 2017. p. 399-408 https://doi.org/10.1007/978-1-4419-0717-2_32
Childs, William Richard ; Pantin, Jeremy Mark. / NK Cells. Cancer Therapeutic Targets. Vol. 1-2 Springer New York, 2017. pp. 399-408
@inbook{24172d7f155046b9b51defe386423c56,
title = "NK Cells",
abstract = "Natural killer (NK) cells are innate immune lymphocytes that express CD56 and lack CD3 surface antigens. NK cells do not require the presence of specific tumor antigen for the recognition and killing of cancer cells. NK cell recognition of tumor targets is regulated through a balance of activating and inhibitory signals. NK cells also have the ability to directly kill target cells through antibodydependent cell cytotoxicity (ADCC) via the membrane Fc-? receptor III (CD16) which binds to IgG antibodies and can also indirectly induce tumor apoptosis through cytokine secretion, directly through the perforin-granzyme pathway, or through death-receptor ligands such as TRAIL or Fas ligand expressed on their cell surfaces. Tumors with low HLA class I expression are more susceptible to NK cell cytotoxicity. Adoptive infusion of allogeneic NK cells in patients who lack MHC class I molecules for one or more KIRs present in the donor may overcome NK cell-mediated KIR inactivation. Agents that increase surface expression of cellular death-receptors which render tumors more susceptible to NK cell cytotoxicity include bortezomib and depsipeptide. In vitro expanded autologous NK cells isolated from patients with cancers have been shown to exhibit significantly more cytotoxicity when tumors were pretreated with bortezomib compared with untreated tumor controls. Combining adoptive NK cell transfer with monoclonal antibody therapy could augment NK cell-mediated ADCC.",
keywords = "ADCC, Antibody-dependent cell cytotoxicity (ADCC), CAR, Chimeric antigen receptors (CAR), Clinical trials, Effector assessment, IL-2 activation, In cancer, In vitro and in vivo susceptibility, Interleukin-2 (IL-2), Killer immunoglobulin-like receptors (KIRs), KIR-mediated inactivation of, Natural killer (NK) cells, Tumor susceptibility",
author = "Childs, {William Richard} and Pantin, {Jeremy Mark}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-0717-2_32",
language = "English (US)",
isbn = "9781441907165",
volume = "1-2",
pages = "399--408",
booktitle = "Cancer Therapeutic Targets",
publisher = "Springer New York",
address = "United States",

}

TY - CHAP

T1 - NK Cells

AU - Childs, William Richard

AU - Pantin, Jeremy Mark

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Natural killer (NK) cells are innate immune lymphocytes that express CD56 and lack CD3 surface antigens. NK cells do not require the presence of specific tumor antigen for the recognition and killing of cancer cells. NK cell recognition of tumor targets is regulated through a balance of activating and inhibitory signals. NK cells also have the ability to directly kill target cells through antibodydependent cell cytotoxicity (ADCC) via the membrane Fc-? receptor III (CD16) which binds to IgG antibodies and can also indirectly induce tumor apoptosis through cytokine secretion, directly through the perforin-granzyme pathway, or through death-receptor ligands such as TRAIL or Fas ligand expressed on their cell surfaces. Tumors with low HLA class I expression are more susceptible to NK cell cytotoxicity. Adoptive infusion of allogeneic NK cells in patients who lack MHC class I molecules for one or more KIRs present in the donor may overcome NK cell-mediated KIR inactivation. Agents that increase surface expression of cellular death-receptors which render tumors more susceptible to NK cell cytotoxicity include bortezomib and depsipeptide. In vitro expanded autologous NK cells isolated from patients with cancers have been shown to exhibit significantly more cytotoxicity when tumors were pretreated with bortezomib compared with untreated tumor controls. Combining adoptive NK cell transfer with monoclonal antibody therapy could augment NK cell-mediated ADCC.

AB - Natural killer (NK) cells are innate immune lymphocytes that express CD56 and lack CD3 surface antigens. NK cells do not require the presence of specific tumor antigen for the recognition and killing of cancer cells. NK cell recognition of tumor targets is regulated through a balance of activating and inhibitory signals. NK cells also have the ability to directly kill target cells through antibodydependent cell cytotoxicity (ADCC) via the membrane Fc-? receptor III (CD16) which binds to IgG antibodies and can also indirectly induce tumor apoptosis through cytokine secretion, directly through the perforin-granzyme pathway, or through death-receptor ligands such as TRAIL or Fas ligand expressed on their cell surfaces. Tumors with low HLA class I expression are more susceptible to NK cell cytotoxicity. Adoptive infusion of allogeneic NK cells in patients who lack MHC class I molecules for one or more KIRs present in the donor may overcome NK cell-mediated KIR inactivation. Agents that increase surface expression of cellular death-receptors which render tumors more susceptible to NK cell cytotoxicity include bortezomib and depsipeptide. In vitro expanded autologous NK cells isolated from patients with cancers have been shown to exhibit significantly more cytotoxicity when tumors were pretreated with bortezomib compared with untreated tumor controls. Combining adoptive NK cell transfer with monoclonal antibody therapy could augment NK cell-mediated ADCC.

KW - ADCC

KW - Antibody-dependent cell cytotoxicity (ADCC)

KW - CAR

KW - Chimeric antigen receptors (CAR)

KW - Clinical trials

KW - Effector assessment

KW - IL-2 activation

KW - In cancer

KW - In vitro and in vivo susceptibility

KW - Interleukin-2 (IL-2)

KW - Killer immunoglobulin-like receptors (KIRs)

KW - KIR-mediated inactivation of

KW - Natural killer (NK) cells

KW - Tumor susceptibility

UR - http://www.scopus.com/inward/record.url?scp=85038961932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038961932&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0717-2_32

DO - 10.1007/978-1-4419-0717-2_32

M3 - Chapter

AN - SCOPUS:85038961932

SN - 9781441907165

VL - 1-2

SP - 399

EP - 408

BT - Cancer Therapeutic Targets

PB - Springer New York

ER -